Spot on Half,
A DRE is simply a blind tactile test. You can feel only a grossly enlarged prostate or other intervening organ. In females you can also palpate inflamed feminine organs if they begin to impinge on the last inch or two of the orifice. You are completely blind to cell type and cannot adequately "screen" someone for cancer although that is one of the benefits of doing a DRE. It's like a breast exam for women: you can feel it if there's a lump already, but you cannot identify cell type and therefore will miss young tumors and any that are of a sneaky consistency.
A test like RECAF is a great complement to today's SOC (standard of care). It's absolutely absurd to think that it isn't. You like to point to other companies having difficulty getting their universal marker going and use that as reason to conclude that a reliable universal marker isn't useful in healthcare. If anyone believes that "logic," that person is likely not competent to handle their own affairs. A reliable universal cancer marker that can identify dis-regulated dividing cells via a blood test is a phenomenal component to aid in cancer identification when superficial tests like DRE's and breast exams don't work. You identify a tumor earlier, your treatment and prognosis are that much better. You identify a patient with a possible tumor sooner, and you can get them back in 6 months or less for a check up, monitor them more closely because you now have advanced warning of a neoplasmic process, and again prognosis for that patient gets better.
The science is there. The science works and is needed. There's a lot more to this than just science. It's also a business. Like you pointed out, some of the other businesses haven't been going so well. Guess what? Neither has BioCurex to this point, which is why it's hovering around 7¢. That said, from a business standpoint, with the $6M in brand new funding, they are better prepared to get the ball rolling on some of this phenomenal technology then they were 2 months ago or even 8 months ago. And, from an investor's standpoint (call me crazy, but I actually am one), the low price per share with the new funding and a product with real utility and potential make this a very reasonable chance to take.
You seem quite determined to make negative points all day. Feel free, it's a free country. But, don't fool yourself into thinking you're going to change an intelligent mind on this board. This is as good an entry point as I've seen in a stock all year, and that includes a number of winning plays.
Cheers and GLTA the longs!
BK
